Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients

[1]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[2]  Julián Esparza Romero,et al.  Impacto del tratamiento antineoplásico en el estado nutricional en pacientes con cáncer de mama , 2014 .

[3]  B. Ljung,et al.  Breast Cancer, Version 3.2013 , 2013 .

[4]  Richard Sullivan,et al.  Planning cancer control in Latin America and the Caribbean. , 2013, The Lancet. Oncology.

[5]  J. V. Von Roenn,et al.  American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Griggs,et al.  American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. , 2010, Journal of oncology practice.

[7]  P. Clézardin,et al.  How do bisphosphonates inhibit bone metastasis in vivo? , 2010, Neoplasia.

[8]  J. Mackey,et al.  Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Almeida,et al.  The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. , 2010, Molecular endocrinology.

[10]  M. Tisdale.  Mechanisms of cancer cachexia. , 2009, Physiological reviews.

[11]  A. Mohar,et al.  Recursos disponibles para el tratamiento del cáncer de mama en México , 2009 .

[12]  Tony Reiman,et al.  Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. , 2008, The Lancet. Oncology.

[13]  R. Roubenoff.  Excess baggage: sarcopenia, obesity, and cancer outcomes. , 2008, The Lancet. Oncology.

[14]  P. Delmas,et al.  Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. , 2007, Bone.

[15]  R. Wolff,et al.  Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women , 2007, Breast Cancer Research and Treatment.

[16]  S. Cawthorn,et al.  Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. , 2007, The Lancet. Oncology.

[17]  J. Cuzick,et al.  Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2‐Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230) , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  F. López-Soriano,et al.  Fisiología de la sarcopenia: Similitudes y diferencias con la caquexia neoplásica , 2006 .

[19]  R. Baumgartner,et al.  Association of body composition and weight history with breast cancer prognostic markers: divergent pattern for Hispanic and non-Hispanic White women. , 2004, American journal of epidemiology.

[20]  J. Cauley,et al.  American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  T. Powles,et al.  Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Parker,et al.  Instant vertebral assessment: a noninvasive dual X-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis. , 2001, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[23]  J. Manola,et al.  Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Winer,et al.  Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Blomqvist,et al.  Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  P. Delmas,et al.  Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Roberto Pacifici,et al.  Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  R. Jilka,et al.  Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. , 1995, The New England journal of medicine.

[29]  T. Byers,et al.  Behavioral risk factors and their relationship to tumor characteristics in Hispanic and non-Hispanic white long-term breast cancer survivors , 2011, Breast Cancer Research and Treatment.

[30]  N. Berger.  Cancer and Energy Balance, Epidemiology and Overview , 2010 .

[31]  A. Mohar,et al.  [Available resources for the treatment of breast cancer in Mexico]. , 2009, Salud publica de Mexico.

[32]  C. Lawton.  Ten-Year Follow-Up of 3 Years of Oral Adjuvant Clodronate Therapy Shows Significant Prevention of Osteoporosis in Early-Stage Breast Cancer , 2009 .

[33]  G. Francini,et al.  Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. , 2007, Bone.

[34]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[35]  M. Perry.  Companion handbook to The chemotherapy source book , 1999 .